Tissue factor activity of blood mononuclear cells is increased after total knee arthroplasty

Thrombosis and Haemostasis

Volumn 102, Issue 4, 2009, Pages 728-734

  Johnson, Gerhard J ^a,b   Leis, Linda A ^a   Bach, Ronald R ^a,b  

^a VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Blood platelets; Knee arthroplasty; Leukocyte procoagulant activity; Tissue factor

Indexed keywords

PROCOAGULANT; THROMBOPLASTIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MONONUCLEAR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK FACTOR; SURGICAL TECHNIQUE; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, KNEE; BIOLOGICAL MARKERS; BLOOD COAGULATION; CALCIUM; CASE-CONTROL STUDIES; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; THROMBOPLASTIN; VENOUS THROMBOEMBOLISM;

EID: 70449508204     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-04-0261     Document Type: Article

References (49)

1. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990; 87: 6934-6938. (Pubitemid 20325179)
2. Eilertsen KE, Østerud B. Tissue factor: (patho)physiology and cellular biology. Blood Coagul Fibrinolysis 2004; 15: 521-538.
3. Giesen PLA, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, et al. Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-2315. (Pubitemid 29117911)
4. Butenas S, Bouchard BA, Brummel-Ziedins KE, Parhami-Seren B, Mann KG. Tissue factor activity in whole blood. Blood 2005; 105: 2764-2770. (Pubitemid 40446267)
5. Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol 2006; 26: 456-461.
6. Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, Eichinger S, et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007; 97: 119-123. (Pubitemid 46242392)
7. Steffel J, Lüscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006; 113: 722-731. (Pubitemid 43754336)
8. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007; 5: 520-527.
9. Gentile NT, Vaidyula VR, Kanamalla U, DeAngelis M, Gaughan J, Rao AK. Factor VIIa and tissue factor procoagulant activity in diabetes mellitus after acute ischemic stroke: Impact of hypergylcemia. Thromb Haemost 2007; 98: 1007-1013. (Pubitemid 350091129)
10. Kamikura Y, Wada H, Nobori T, Kobayashi T, Sase T, Nishikawa M, et al. Elevated levels of leukocyte tissue factor mRNA in patients with venous thromboembolism. Thromb Res 2005; 116: 307-312. (Pubitemid 40994913)
11. Morange PE, Blankenberg S, Alessi MC, Bickel C, Rupprecht HJ, Schnabel R, et al. Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 2007; 5: 475-482. (Pubitemid 46680678)
12. Rao AK, Vaidyula VR, Bagga S, Jalagadugula G, Gaughan J, Wilhite DB, et al. Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease. Thromb Haemost 2006; 96: 738-743. (Pubitemid 44883813)
13. Vieira LM, Dusse LMS, Fernandes AP, Martins- Filho OA, de Bastos M, Ferreira MFR, et al. Monocytes and plasma tissue factor levels in normal individuals and patients with deep venous thrombosis of the lower limbs: potential diagnostic tools? Thromb Res 2007; 119: 157-165.
14. Huisse MG, Ajzenberg N, Feldman L, Guillin MC, Steg PG. Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction. Thromb Haemost 2009; 101: 734-740.
15. Nylaende M, Kroese A, Stranden E, Morken B, Sandbaek G, Lindahl AK, et al. Prothrombotic activity is associated with the anatomical as well as the functional severity of peripheral arterial occlusive disease. Thromb Haemost 2006; 95: 702-707.
16. Parhami-Seren B, Butenas S, Krudysz-Amblo J, Mann KG. Immunologic quantitation of tissue factor. J Thromb Haemost 2006; 4: 1747-1755.
17. Maly M, Hrachovinova I, Tomasov P, Salaj P, Hajek P, Veselka J. Patients with acute coronary syndromes have low tissue factor activity and microparticle count, but normal concentration of tissue factor antigen in platelet free plasma - a pilot study. Eur J Haematol 2008; 82: 148-153.
18. Del Turco S, Basta G, Lazzerini G, Evangelista M, Rainaldi G, Tanganelli P, et al. Effect of the administration of n-3 polyunsaturated fatty acids on circulating levels of microparticles in patients with a previous myocardial infarction. Haematologica 2008; 93: 892-899. (Pubitemid 351821726)
19. Bonderman D, Teml A, Jakowitsch J, Adlbrecht C, Gyöngyösi M, Sperker W, et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherocsclerotic plaque. Blood 2002; 99: 2794-2800. (Pubitemid 34525367)
20. Del Conde I, Bharwani LD, Dietzen DJ, Pendurthi U, Thiagarajan P, López JA. Microvesicle-associated tissue factor and Trousseau's syndrome. J Thromb Haemost 2007; 5: 70-74. (Pubitemid 44921069)
21. Amini-Nekoo A, Futers TS, Moia M, Mannucci PM, Grant PJ, Ariëns RAS. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br J Haematol 2001; 113: 537-543. (Pubitemid 32523166)
22. Dahm A, Rosendaal FR, Andersen TO, Sandset PM. Tissue factor pathway inhibitor anticoagulant activity: risk for venous thrombosis and effect of hormonal state. Br J Haematol 2006; 132: 333-338. (Pubitemid 43381540)
23. Morrow DA, Murphy SA, McCabe CH, Mackman N, Wong HC, Antman EM. Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 Trial. Eur Heart J 2005; 26: 682-688. (Pubitemid 40516880)
24. Lee A, Agnelli G, Büller H, Ginsberg J, Heit J, Rote W, et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001; 104: 74-78. (Pubitemid 32623292)
25. Himber J, Wohlgensinger C, Roux S, Damico LA, Fallon JT, Kirchhofer D, et al. Inhibition of tissue factor limits the growth of venous thrombus in the rabbit. J Thromb Haemost 2003; 1: 889-895.
26. Szalony JA, Suleymanov OD, Salyers AK, Panzer- Knodle SG, Blom JD, LaChance RM, et al. Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time. Thromb Res 2003; 112: 167-174.
27. Colwell CW Jr., Hardwick ME. Rationale for low-molecular- weight heparin prophylaxis after total knee arthroplasty. Clin Orthop Relat Res 2006; 452: 181-185.
28. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381S-453S. (Pubitemid 351894916)
29. Kageyama K, Nakajima Y, Shibasaki M, Hashimoto S, Mizobe T. Increased platelet, leukocyte, and endothelial cell activity are associated with increased coagulability in patients after total knee arthroplasty. J Thromb Haemost 2007; 5: 738-745. (Pubitemid 46563572)
30. Bach RR, Johnson GJ, Long JR, Key NS. Intravascular tissue factor procoagulant activity increases following joint replacement surgery. J Thromb Haemost 2003; 1 (Suppl 1): P0536.
31. Henriksson CE, Klingenberg O, Ovstebo R, Joo GB, Westvik AB, Kierulf P. Discrepancy between tissue factor activity and tissue factor expression in endotoxin- induced monocytes is associated with apoptosis and necrosis. Thromb Haemost 2005; 94: 1236-1244. (Pubitemid 41819622)
32. Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 1986; 25: 4007-4020. (Pubitemid 16045624)
33. Carson SD, Ross SE, Bach RR, Guha A. An inhibitory monoclonal against human tissue factor. Blood 1987; 70: 490-493. (Pubitemid 17142934)
34. Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998; 91: 4216-4223. (Pubitemid 28261985)
35. Osterud B, Due J, Jr. Blood coagulation in patients with benign and malignant tumours before and after surgery. Special reference to thromboplastin generation in monocytes. Scand J Haematol 1984; 32: 258-264. (Pubitemid 14151495)
36. Chung J, Tabuchi N, Koyama T. The increase in tissue factor-bearing leukocytes after off-pump coronary artery bypass surgery. Thromb Haemost 2008; 100: 952-954.
37. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158: 1525-1531. (Pubitemid 28340985)
38. Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA Jr, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. J Bone Joint Surg Am 2001; 83-A: 336-345.
39. Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L'Espérance B, Demers C, et al. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996; 124: 619-626.
40. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 1687-1693. (Pubitemid 47207163)
41. Del Turco S, Basta G, Lazzerini G, Evangelista M, Rainaldi G, Tanganelli P, et al. Effect of the administration of n-3 polyunsaturated fatty acids on circulating levels of microparticles in patients with a previous myocardial infarction. Haematologica 2008; 93: 892-899. (Pubitemid 351821726)
42. Koyama T, Nishida K, Ohdama S, Sawada M, Murakami N, Hirosawa S, et al. Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol 1994; 87: 343-347. (Pubitemid 24204737)
43. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nature Med 2003; 9: 458-462. (Pubitemid 36460081)
44. Bogdanov VY, Kirk RI, Miller C, Hathcock JJ, Vele S, Gazdoiu M, et al. Identification and characterization of murine alternatively spliced tissue factor. J Thromb Haemost 2006; 4: 158-167.
45. Censarek P, Bobbe A, Grandoch M, Schrör K, Weber A-A. Alternatively spliced human tissue factor (asHTF) is not pro-coagulant. Thromb Haemost 2007; 97: 11-14. (Pubitemid 46242381)
46. Hobbs JE, Zakarija A, Cundiff DL, Doll JA, Hymen E, Cornwell M, et al. Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res 2007; 120 (Suppl 2): S13-S21. (Pubitemid 350101769)
47. Szotowski B, Antoniak S, Poller W, Schultheiss HP, Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 2005; 96: 1233-1239. (Pubitemid 40962100)
48. Levine SJ. Molecular mechanisms of soluble cytokine receptor generation. J Biol Chem 2008; 283: 14177-14181.
49. He Y, Chang G, Zhan S, Song X, Wang X, Luo Y. Soluble tissue factor has unique angiogenic activities that selectively promote migration and differentiation but not proliferation of endothelial cells. Biochem Biophys Res Comm 2008; 370: 489-494.